Bayer Leverkusen are set to complete the signing of Brentford goalkeeper Mark Flekken (31).According to Florian Plettenberg, ...

You rarely get a second chance to say goodbye. I guess I must be one of the lucky ones in football, because I’m getting that ...

The manager Kovac will pick his starting XI against Bayer Leverkusen from these players: Alexander Meyer (0/2), Gregor Kobel (0/30), Almugera Kabar (0/5), Daniel Svensson (1/10), Filippo Mane (0/0), ...

The FDA elevated a recall of intraocular lenses currently being wrapped up by Bausch + Lomb, following increased reports of inflammatory reactions from patients who underwent cataract surgery.

Niklas Süle's return to fitness and form has fuelled Borussia Dortmund's late charge up the Bundesliga table as he has filled the void left by the injured Nico Schlotterbeck. bundesliga.com takes ...

Bausch + Lomb has recalled lenses used during cataract surgery due to complications when the lenses are used, according to an announcement from the Canada-based eyecare company posted on the U.S ...

Bausch + Lomb shares tumbled in intraday trading Friday, a day after the eye-care company announced a "voluntary recall" of some of its intraocular lenses due to safety concerns. On Thursday ...

Shares of eyecare company Bausch + Lomb (NYSE:BLCO) fell 10.6% in the afternoon session after the company announced the voluntary recall of intraocular lenses on its enVista platform. The recall ...

Please provide your email address to receive an email when new articles are posted on . Bausch + Lomb has received reports of toxic anterior segment syndrome in patients with enVista IOLs.

Prices from the bookmakers reflect how much they expect Bayer Leverkusen to pull away with 3 points this coming Saturday. They face Werder Bremen in the Bundesliga and the latter could be in for a ...

Eyecare company Bausch + Lomb (NYSE:BLCO) will be announcing earnings results tomorrow morning. Here’s what to expect. Bausch + Lomb beat analysts’ revenue expectations by 1.6% last quarter ...

Twenty-one months into his second tenure as CEO of Bausch + Lomb, serial dealmaker Brent Saunders has so far come up empty in his latest attempt to sell the company. But it hasn’t been for lack ...